Open

Study of MRTX1719 in Patients with Advanced Cancer and a Specific Genetic Change

This study is testing a new drug called MRTX1719. The main goal is to find the best dose of the drug to use in future studies. The study will also look at what side effects the drug may cause and how often they happen. Researchers will also measure how quickly the drug is absorbed into the bloodstream and how fast the body gets rid of it. Additionally, they will check how well MRTX1719 works against cancer.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

What will be asked of you

Here's what you can expect during the study: - You will take the study drug in pill form. - Depending on the phase of the study, you will visit the clinic for blood draws to check how the drug is processed in your body. - During these visits, you will also be asked about your physical well-being to monitor any effects of the treatment.

Incentives

Study drug

In-person visits:
All

Total length of participation:
Until disease progression

Looking for Specific Volunteers

Able to participate:

History of Solid tumor with the deletion of MTAP gene
Unresectable or metastatic disease
No available treatment for your cancer
Life expectancy of at least 3 months

Not eligible if:

Active brain cancer
Major surgery within 4 weeks of first dose of study treatment
History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions
History of stroke within the last 6 months

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clincal Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Shetal Patel
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lung, Pancreatic, Phase 1 Trials (all cancers))

IRB Number

23-2686

ClinicalTrials.gov

NCT05245500

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.